Simulations Plus (SLP) Stock Analysis & Winston Score

Simulations Plus makes specialized software used by pharmaceutical and biotechnology companies to predict how drugs behave inside the human body. Its main products — including GastroPlus and ADMET Predictor — help scientists simulate how a drug is absorbed, distributed, and eliminated, reducing the need for costly lab experiments. The company also offers consulting services where its own scientists help drug developers interpret results and run analyses. The company earns money through software licenses and subscriptions, as well as fees from its consulting work. It operates primarily in North America, Europe, and Asia, serving major drug companies, generic manufacturers, and regulatory agencies like the FDA. Its moat comes from deep scientific credibility and the fact that its software is embedded in drug development workflows that are expensive and risky to change. The key risk is its small size — with a market cap around $400 million — which makes it vulnerable to competition from larger software vendors expanding into life sciences modeling.